PHATHOM PHARMACEUTICALS, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2017 | — | $0 | — |
| Mar 2018 | — | $-252.0K | — |
| Jun 2018 | — | $-512.0K | — |
| Sep 2018 | — | $-802.0K | — |
| Dec 2018 | — | $-1.3M | $879.0K |
| Mar 2019 | — | $-2.5M | — |
| Jun 2019 | — | $-84.4M | — |
| Sep 2019 | $22.6M | $-152.5M | $74.5M |
| Dec 2019 | $22.8M | $228.0M | $243.8M |
| Mar 2020 | $45.9M | $208.7M | $256.7M |
| Jun 2020 | $44.9M | $188.4M | $247.3M |
| Sep 2020 | $41.1M | $156.4M | $226.4M |
| Dec 2020 | $39.6M | $194.3M | $287.5M |
| Mar 2021 | $35.6M | $164.3M | $238.0M |
| Jun 2021 | $37.3M | $132.1M | $209.7M |
| Sep 2021 | $88.3M | $103.5M | $224.6M |
| Dec 2021 | $89.7M | $72.2M | $183.3M |
| Mar 2022 | $91.0M | $38.0M | $138.1M |
| Jun 2022 | $92.4M | $-7.0M | $207.4M |
| Sep 2022 | $93.9M | $-26.4M | $196.8M |
| Dec 2022 | $95.3M | $-74.8M | $155.4M |
| Mar 2023 | $96.6M | $-90.2M | $129.6M |
| Jun 2023 | $97.8M | $17.6M | $248.8M |
| Sep 2023 | $99.3M | $-17.8M | $213.7M |
| Dec 2023 | $137.8M | $-72.8M | $381.4M |
| Mar 2024 | $149.0M | $-148.5M | $322.2M |
| Jun 2024 | $174.4M | $-233.8M | $276.2M |
| Sep 2024 | $175.7M | $-187.1M | $334.7M |
| Dec 2024 | $201.4M | $-253.6M | $297.3M |
| Mar 2025 | $203.2M | $-338.4M | $212.3M |
| Jun 2025 | $205.1M | $-405.8M | $149.6M |
| Sep 2025 | $207.1M | $-422.5M | $135.2M |
| Dec 2025 | $209.1M | $-438.2M | $130.0M |
| Mar 2026 | $163.7M | $-337.0M | $180.9M |
| Jun 2026 | $164.6M | $-344.3M | $182.5M |